Evidence map›Paper›PMID 41639379›Full record

Trial reportNature medicine2026

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial.

Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, Koichi Goto, Adrianus Johannes de Langen, Dong-Wan Kim, Jürgen Wolf, Christoph Springfeld, Sanjay Popat, Darren W T Lim and 14 more

Abstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Evidence and gaps in tumor-agnostic therapies for breast cancer: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026
    Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Benjamin BesseParis-Saclay University, Gustave Roussy Cancer Center, Villejuif, France. Benjamin.BESSE@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-5090-8189
Jessica J LinMass General Brigham Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7373-3916
Lyudmila BazhenovaUniversity of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Koichi GotoNational Cancer Center Hospital East, Kashiwa, Japan.ORCID http://orcid.org/0000-0002-3023-2510
Adrianus Johannes de LangenNetherlands Cancer Institute, Amsterdam, Netherlands.ORCID http://orcid.org/0000-0001-7343-633X
Dong-Wan KimSeoul National University Hospital, Seoul, South Korea.ORCID http://orcid.org/0000-0001-5124-7132
Jürgen WolfCenter for Integrated Oncology, University Hospital Cologne, Cologne, Germany.
Christoph SpringfeldHeidelberg University Hospital, National Center for Tumor Diseases, Department of Medical Oncology, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-3843-101X
Sanjay PopatThe Royal Marsden NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0003-2087-4963
Darren W T LimNational Cancer Centre Singapore, Singapore, Singapore.ORCID http://orcid.org/0000-0002-4655-0206
Misako NagasakaUniversity of California, Irvine, School of Medicine, Orange, CA, USA.
Jung Yong HongSamsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Christina S BaikUniversity of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Alice HervieuCentre Georges-François Leclerc, Dijon, France.
Victor MorenoSTART MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain.ORCID http://orcid.org/0000-0001-6099-4236
Nong YangThe Second People's Hospital of Hunan Province, Hunan, China.
Kanthi KollengodeBristol Myers Squibb, Princeton, NJ, USA.
Haisu YangBristol Myers Squibb, Princeton, NJ, USA.
Yuanfang XuBristol Myers Squibb, Princeton, NJ, USA.
Christophe Y CalvetBristol Myers Squibb, Princeton, NJ, USA.
Yong YuanBristol Myers Squibb, Princeton, NJ, USA.
Amy B HammellBristol Myers Squibb, Princeton, NJ, USA.
Alexander Drilon *Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.ORCID http://orcid.org/0000-0001-6806-9061
Benjamin J Solomon *Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0003-3059-5730

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted TherapyR01CA273224 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael F. Berger, Alexander Drilon · 2022 to 2026
$3.6M
Understanding tumor addiction to TRK fusions and sensitivity to TRK inhibitionR01CA226864 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DRILON, ALEXANDER, VENTURA, ANDREA · 2018 to 2021
$2.5M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA226864NCI NIH HHS R01 CA273224
6 · The paper itself

Abstract

Early-generation TRK tyrosine kinase inhibitors (TKIs) approved for treating NTRK fusion-positive (NTRK

Indexed as

Macrocyclic CompoundsNeoplasmsOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalPyrimidinesReceptor, trkAReceptor, trkBMacrocyclic CompoundsOncogene Proteins, FusionProtein Kinase InhibitorsPyrazolesPyrimidinesReceptor, trkAReceptor, trkBrepotrectinib

Identifiers

PMID41639379
PMCPMC12920079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.